GHRH-analog family with distinct DAC and non-DAC active moieties
CJC-1295 is a name used for more than one GHRH-related molecule. Small human studies of the long-acting DAC form show sustained GH and IGF-1 changes, but they did not test the recovery, sleep, muscle, fat-loss, or anti-aging outcomes commonly promoted online.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Small short-term studies measured GH, IGF-1, and pharmacokinetics for the DAC active moiety; clinical outcomes remain unestablished.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The DAC pharmacology signal is traceable, but promoted outcomes, long-term safety, and all no-DAC claims lack controlled human support.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: These data appear to involve CJC-1295 DAC free base with the salt unspecified. They do not establish benefit, an approved schedule, or any property of no-DAC/Mod GRF(1-29). Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
The short version
CJC-1295 is a name used for more than one GHRH-related molecule. Small human studies of the long-acting DAC form show sustained GH and IGF-1 changes, but they did not test the recovery, sleep, muscle, fat-loss, or anti-aging outcomes commonly promoted online.
Separates CJC-1295 DAC human studies from non-DAC/Mod GRF naming, includes the terminated Phase 2 registration, FDA's November 2024 evidence review, December 2024 advisory votes, and the 2026 WADA list.
What the evidence says
Two small randomized, placebo-controlled pharmacology studies in healthy adults found sustained GH and IGF-1 increases after CJC-1295 DAC exposure. They measured hormone responses, not meaningful health outcomes.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Clinical benefits, repeat-exposure and long-term safety, product identity across commonly conflated forms, and whether any findings apply to non-DAC/Mod GRF(1-29).
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
Mean and trough GH and IGF-1 increased while measurable pulsatile GH secretion persisted.
A single injection produced dose-dependent increases in mean GH for at least six days and IGF-1 for about 9–11 days. Repeated exposure kept mean IGF-1 above baseline for up to 28 days.
No results are posted. Development stopped after a participant experienced a fatal myocardial infarction during the trial.
Administration and handling
Published human pharmacology used subcutaneous CJC-1295 DAC at protocol-defined research doses. The studies are descriptions of experimental arms, not approved dosing instructions, and they do not establish administration for non-DAC/Mod GRF products. No FDA-approved CJC-1295 product, consumer dose, route, schedule, injection site, or reconstitution procedure exists.
No FDA-approved product-specific reconstitution or storage instructions were located. FDA described major uncertainty around active-moiety and salt identity, aggregation, impurities, formulation, sterility, endotoxins, and immunogenicity. A bulk-material storage observation or supplier instruction should not be converted into universal guidance for a prepared injectable product.
Primary-source ledger
2026-01-01
2024-12-04
2024-11-15
2006-12-01 · PMID 17018654 · DOI 10.1210/jc.2006-1702
2006-03-01 · PMID 16352683 · DOI 10.1210/jc.2005-1536
2005-12-23 · NCT00267527